Deals of the day-Mergers and acquisitions
Adds: CVS, Frasers Group, Tetragon,
Oct 11 (Reuters) -The following bids, mergers, acquisitions and disposals were reported by 2000GMT on Friday:
** CVS Health CVS.N is exiting its core infusion services business and plans to either close or sell 29 related regional pharmacies in the coming months, a company spokesperson confirmed to Reuters on Friday. nL1N3LN0ZJ
** British sportswear and apparel retailer Frasers Group FRAS.L revised its takeover bid for Mulberry MUL.L to 150 pence per share on Friday, valuing the company at 111 million pounds ($145.11 million). nL4N3LN1H4
** Saudi Arabia's Public Investment Fund is not currently in talks to buy a stake in DAZN, the sports-streaming group backed by billionaire Len Blavatnik, PIF said in a statement on Friday. nL8N3LN1NM
** Investment group Tetragon TFG.AS is looking at options for British infrastructure investor Equitix, including a possible sale, two people with knowledge of the matter said, potentially adding to a rush of deals by funds in alternative assets. nL8N3LN0MG
** Nippon Steel 5401.T said it will sell its entire 50% stake in a joint-venture steel plant it has in Calvert, Alabama, with ArcelorMittal MT.LU, if the top Japanese steelmaker succeeds in a buyout bid for United States Steel X.N.
nL1N3LN07I
** Sanofi SASY.PA has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice, the French pharmaceutical group said.
nL1N3LN07L
** Italy's Brembo BRBI.MI said it had agreed to buy suspension technology manufacturer Ohlins Racing for $405 million, in the premium brake maker's biggest ever acquisition.
nL1N3LN05Z
** British holiday group Saga SAGA.L said that Ageas AGES.BR would buy its insurance underwriting business for 67.5 million pounds ($88.1 million), and that it was in exclusive talks to set up a 20-year partnership for motor and home insurance with the Belgian firm.
nL4N3LN0HC
** Singapore-headquartered private healthcare company Health Management International, or HMI Medical, said it is acquiring a majority stake in Advanced Urology Associates, the largest private urology specialist group in the country.
nL1N3LN02B
** U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which Novo Nordisk's NOVOb.CO controlling shareholder would acquire contract drug manufacturer Catalent CTLT.N, saying it may give the pharmaceutical company an unlawful advantage in obesity drugs.
nL1N3LM0LD
(Compiled by Rajarshi Roy, Puyaan Singh and Jaiveer Shekhawat in Bengaluru)
</body></html>Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
